A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

BACKGROUND: Preclinical findings suggest that imatinib mesylate (IM) and metronomic cyclophosphamide (MC) combination provides synergistic antiangiogenic activity on both pericytes and endothelial cells. METHODS: We have designed a 3+3 dose-escalating phase I trial with a fixed dose of MC (50 mg two...

Descripción completa

Detalles Bibliográficos
Autores principales: Adenis, A, Ray-Coquard, I, Italiano, A, Chauzit, E, Bui-Nguyen, B, Blay, J-Y, Tresch-Bruneel, E, Fournier, C, Clisant, S, Amela, E Y, Cassier, P A, Molimard, M, Penel, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833229/
https://www.ncbi.nlm.nih.gov/pubmed/24149182
http://dx.doi.org/10.1038/bjc.2013.648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833229/
https://www.ncbi.nlm.nih.gov/pubmed/24149182
http://dx.doi.org/10.1038/bjc.2013.648

Ejemplares similares